Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00022711 · ClinicalTrials.gov registry record · Phase 2
Temozolomide in Treating Patients With Relapsed or Progressive Small Cell Lung Cancer
A Phase 2 study, sponsored by Fox Chase Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT00022711: Completed Phase 2 study, sponsored by Fox Chase Cancer Center.
NCT00022711 is a Phase 2 study that has completed, run by Fox Chase Cancer Center. The registered enrollment target is 7 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00022711, a Phase 2 study, has completed, sponsored by Fox Chase Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating patients who have relapsed or progressive small cell lung cancer.
Interventions
- DRUG temozolomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2002-01 |
| Est. Completion | 2004-01 |
| Phase | Phase 2 |
What the finished NCT00022711 record still lists
NCT00022711 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which temozolomide is the first listed.
NCT00022711 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00022711 about?
NCT00022711 is a clinical study titled "Temozolomide in Treating Patients With Relapsed or Progressive Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating patients who have relapsed or progressive small cell lung cancer.
What is the current status of trial NCT00022711?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2002-01. Estimated completion is 2004-01.
What interventions are being tested in trial NCT00022711?
The interventions under investigation include: temozolomide (DRUG).
Who is sponsoring clinical trial NCT00022711?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00022711's enrollment target sits among peer trials
7 1996th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia